Pivtorak K. V., Shevchuk N. A., Pivtorak N. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

The purpose of the study – to evaluate the efficacy, safety of thiotriazolin and L-lysine escinate using and to determine the effect of complex therapy on endothelial function parameters in patients with NAFLD. Object and methods. 135 patients with overweight and obesity were examined. Among them, 46 were overweight (BMI-25-29.9 kg/m2 ), 34 were obesity grade I (BMI-30-34.9 kg/m2 ), and 20 were obese, II grade (BMI-35-39.9 kg/m2 ). 35 patients had normal body mass (BMI 18-24.9 kg/m2 ). We also examined 20 practically healthy persons. All patients were divided into three groups. Patients of the first group received basic therapy (n = 50), in accordance with recommendations of the European Association for the Study of the liver, the European Association for the Study of Diabetes, the European Association for the Study of Obesity. Patients in the second group (n = 60) were assigned baseline therapy and thiotriazoline. Patients in the third group (n = 25), together with baseline treatment and thiotriazoline, were prescribed L-lysine escinate. All subjects were assigned the level of C-reactive protein, endothelin (ET-1) immunoassay using the “hsCRP ELISA” (“DRG” USA) and “Endothelin-1” (“DRG” USA). The activity the Villebrand factor (vWF) was determined by the immune enzyme method used by the company “Shield diagnostics”, Great Britain. The statistical analysis of the obtained results was carried out using the STATISTICA 8 program of Statsoft Company using parametric and nonparametric methods for evaluating the obtained results. Results and discussion. The additional use of thiotriazolin and L-lysine escinate significantly contributed to the concentration of ET-1. The level of ET-1 decreased in patients with NAFLD with normal body mass in 1,5 times, with overweight – in 1,4 times, with obesity I degree – in 1,5 times, with obesity II degree – in 1,6 times (p <0.05) compared with the period before treatment. The level of ET-1 decreased in patients with NAFLD with a normal weight of 20.9%, with overweight – by 16.3%, with obesity 1 degree – by 15.2%, with obesity II degree – by 21.1% (p <0.05) compared with baseline therapy. The concentration of C-reactive protein and von Willebrand factor factor also decreased statistically significantly. Conclusions. Combined therapy of patients with NAFLD by thiotriazolin and L-lysine escinate is an effective way to eliminate endothelial dysfunction, as evidenced by a decreasing the markers of endothelial dysfunction: endothelin-1, Villebrand factor and an inflammatory response marker – C-reactive protein

nonalcoholic fatty liver disease, endothelial dysfunction, treatment, thiotriazolin, L-lysine escinate.

1.  Ivashkin VT, Maevskaya MV, Pavlov ChS, Tihonov IN, Shirokova EN, Bueverov AO, i dr. Klinicheskie rekomendatsii po diagnostike i lecheniyu nealkogolnoy zhirovoy bolezni pecheni Rossiyskogo obschestva po izucheniyu pecheni i Rossiyskoy gastroenterologicheskoy assotsiatsii. Ros. zhurn. gastroenterol., gepatol., koloproktol. 2016;26(2):24-42. [in Russiаn].
2.  Skrypnyk IM, Maslova HS, Havlovskyi OD, Mandryka LYu. Antyoksydantno-prooksydantnyi status u khvorykh na nealkoholnyi steatohepatyt u poiednanni z tsukrovym diabetom 2-ho typu u dynamitsi kompleksnoho patohenetychnoho likuvannia. Visnyk problem biolohii i medytsyny. 2013;1(3):211-6. [in Ukrainian].
3. Babak OYa, Lapshina EA, Babak MO, Chernyak AN. Strategiya lecheniya bolezney pecheni. Rol i mesto ademetionina s pozitsii dokazatelnoy meditsinyi. Suchasna hastroenterolohiia. 2015;1:30-4. [in Ukrainian].
4. Yurev KL. Ademetionin pri boleznyah pecheni. Dokazatelnoe dose. Ukrainskyi medychnyi chasopys. 2011;3:63-9. [in Russiаn].
5. Pankiv VI. Suchasni mozhlyvosti korektsii funktsionalnoho stanu pechinky u khvorykh na tsukrovyi diabet iz vykorystanniam preparatu HepaMerts (LornitynLaspartat). Mizhnarodnyi endokrynolohichnyi zhurnal. 2012;5:36-42. [in Ukrainian].
6. Khukhlina OS, Mandryk OIe, Antoniv AA. Efektyvnist kompleksnoho zastosuvannia hepadyfu, ezetrolu ta fozynoprylu pry nealkoholnomu steatohepatyti u patsiientiv iz hipertonichnoiu khvoroboiu II stadii. Zaporozhskyi medytsynskyi zhurnal. 2013;5:60-3. [in Ukrainian].
7.  Khukhlina OS, Mandryk OIe. Nealkoholnyi steatohepatyt ta hipertonichna khvoroba: osoblyvosti komorbidnoho perebihu, optymizovani pidkhody do likuvannia [monohraffia]. Chernivtsi, Ukraina; 2014. 204 s. [in Ukrainian].
8.  Kravchun NO, Zemlianitsyna OV, Dorosh OH, Cherniavska IV. Dyferentsiiovanyi pidkhid do likuvannia nealkoholnoi zhyrovoi khvoroby pechinky u khvorykh na tsukrovyi diabet 2 typu. Klinichna endokrynolohiia ta endokrynna khirurhiia. 2013;2(43):47-55. [in Ukrainian].
9. Novikov VE, Klimkina EI. Farmakologiya gepatoprotektorov. Obzoryi po klinicheskoy farmakologii i lekarstvennoy terapii. 2005;4(1):2-20. [in Russiаn].
10. Pivtorak KV. Endotelioprotektorna diia tiotryazolinu pry likuvanni khvorykh na nealkoholnu zhyrovu khvorobu pechinky. Materialy VI Konhresu Pivdenno-Skhidno Yevropeiskoho Medychnoho Forumu ta XIV Zizdu Vseukrainskoho Likarskoho Tovarystva (VULT). 2015 veres. 9-12; Odesa. Odesa: Vydavnytstvo Bartienieva; 2015. s. 263. [in Ukrainian].
11. Poluhina AV, Vinnitskaya EV, Bordin DS, Sandler YuG. Nealkogolnaya zhirovaya bolezn pecheni u komorbidnyih patsientov: opyit terapii s ispolzovaniem Tiotriazolina. Effektivnaya farmakoterapiya. Gastroenterologiya. 2018;3(32):20-4. [in Russiаn].
12. Pivtorak KV. Zminy yakosti zhyttia patsiientiv na nealkoholnyi steatohepatyt pislia kompleksnoho likuvannia iz zastosuvanniam kardioprotektornykh zasobiv metabolichnoho typu. Biomedical and biosocial anthropology. 2017;29:119-23. [in Ukrainian].
13. Varlamova NN, Sinelnikova EV, Solodkova IV, Chasnyik VG, Zinoveva EN. Rol endotelialnoy disfunktsii v patogeneze gepatosteatoza u detey. Tendentsii nauki i obrazovaniya v sovremennom mire. 2016;17(1):8-16. DOI: 10.18411/lj2016-8-1-03 [in Russiаn].
14. Papageorgioua MV, Hadziyannisb E, Tiniakosc D, Georgioua A, Margaritib A, Kostasa A, et al. Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease. Annals of Gastroenterology. 2017;30(2):209-16. DOI: 10.20524 / aog.2016.0107
15. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. Journal of hepatology. 2010;53(2):372-84. DOI: https://doi.org/10.1016/j.jhep.2010.04.008
16. Pasarin M, La Mura V, Gracia-Sancho J, Garcia-Caldero H, Rodriguez-Vilarrupla A, Garcia-Pagan JC, et al. Sinusoidal endothelial dysfunction precedes inflammation and fibrosis in a model of NAFLD. PLoS One. 2012;7(4):e32785. Available from: https://doi.org/10.1371/journal. pone.0032785
17.  Pivtorak EV. Primenenie preparatov folievoy i lipoevoy kislot bolnyim steatozom pecheni pri komorbidnyih sostoyaniyah. Eksperimentalnaya i klinicheskaya gastroenterologiya. 2014;105(5):76. [in Russiаn].
18. Zinoveva EN, Mehtiev SN, Sokolovskiy SV. Endotelialnaya disfunktsiya kak faktor progressirovaniya nealkogolnogo steatogepatita. Terapevticheskie podhodyi. Effektivnaya farmakoterapiya. Gastroenterologiya. 2011;2:36-43. [in Russiаn].
19. Khukhlina OS, Drozd VIu. Optymizatsiia likuvannia nealkoholnoho steatohepatytu u khvorykh na ozhyrinnia ta ishemichnu khvorobu sertsia. Liky Ukrainy. 2016;5(205):69-75. [in Ukrainian].
20. Pivtorak KV, Mazur IA, Voloshin MA. Correction of metabolic disorders caused by non-alcoholic fatty liver disease. Deutscherwissenschaftsherold. 2017;4:74-7. DOI: 10.19221/2017424. Available from: http://dwherold.de/onewebmedia/2017/4-2017/Pivtorak%20 74-77.pdf
21. Belenichev IF, Kucherenko LI, Nagornaya EA, Mazur IA, Bidnenko AS, Bukhtiyarova NV, et al. Functional nitric oxide conjugate systems state/ restored heart thiols of rats in modeling isadrinepituitrin’s myocardial infarction using metabolite-tropic cardioprotector “Angiolin”. Int J Basic Clin Pharmacol 2015;4:15-9.
22.  Kolesnyk YuM, Chekman IS, Mazur IA. Belienichev IF, Horchakova NO, Nahorna OO. Mekhanizmy rozvytku endotelialnoi dysfunktsii ta poshuk endotelioprotektoriv. Zhurnal NAMN Ukrainy. 2014;20(3):289-99. [in Ukrainian].
23. Pivtorak KV. Osoblyvosti klitynnoho tsyklu hepatotsytiv pry eksperymentalnii nealkoholnii zhyrovii khvorobi pechinky ta yii korektsii. Visnyk problem biolohii i medytsyny. 2017;1(135):270-4. [in Ukrainian].
24.  Pivtorak KV, Mazur IA, Voloshyn MA. Ultrastrukturna orhanizatsiia endoteliotsytiv pechinky za umov korektsii steatozu novoiu biolohichno aktyvnoiu spolukoiu Anhiolin. Patolohiia. 2015;3(35):49-52. DOI: http://dx.doi.org/10.14739/2310-1237.2015.3.55587 [in Ukrainian].
25. Desiateryk VI, Mamchur DV, Kotov OV, Dronov SM, Zhyliuk VI. Koreliatsiia okremykh biokhimichnykh pokaznykiv funktsionalnoho stanu pechinky v umovakh eksperymentalnoi mekhanichnoi zhovtianytsi i kursovoho vvedennia L-lizynu estsynatu ta hlutarhinu. Medychni perspektyvy. 2016;21(4):8-15. [in Ukrainian].
26. Mamchur DV, Desiateryk VI, Zhyliuk VI, Lievykh AE, Abramov AV. Vyznachennia vplyvu L-lizynu estsynatu ta hlutarhinu na systemu oksydu azotu ta morfometrychnu kharakterystyku endoteliotsytiv pechinky shchuriv z mekhanichnoiu zhovtianytseiu. Kharkivska khirurhichna shkola. 2017;2(83):7-11. [in Ukrainian].
27. Lteif A, Vaishnava P, Baron AD, Mather KJ. Endothelin limits insulin action in obese/insulin-resistant humans. Diabetes. 2007;56(3):728-34.
28. Vozniuk LA, Pivtorak KV, Semenenko SI. Faktor Villebranda yak kryterii zapalennia i dysfunktsii endoteliiu u khvorykh na ishemichnu khvorobu sertsia. Visnyk problem biolohii ta medytsyny. 2012;1(92):39-43. [in Ukrainian].
29. Hontsariuk DO, Khrystych TM, Fediv OI, Teleki YaM. Rol S-reaktyvnoho bilka v rozvytku khronichnoi zapalnoi reaktsii, aterosklerozu, insulinorezystentnosti u khvorykh iz poiednanniam aterosklerozu ta khronichnoho pankreatytu. Praktychna anhiolohiia. 2012;3-4(52-53):21- 5. [in Ukrainian].
30. Parfenov VA. Ispolzovanie L-lizina estsinata pri zabolevaniyah tsentralnoy nervnoy sistemyi. Nevrologiya, neyropsihiatriya, psihosomatika. 2011;4:99-102. [in Russiаn].

«Bulletin of problems biology and medicine» Issue 2 Part 1 (150), 2019 year, 176-181 pages, index UDK 616.36-003.826-092:616.175.8

10.29254/2077-4214-2019-2-1-150-176-181